Monopar Therapeutics — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Monopar announced on July 22, 2026, that it has initiated a rolling New Drug Application (NDA) submission to the FDA for ALXN1840 (tiomolibdate choline), a first-in-class treatment for Wilson disease. The company has already submitted completed sections of the NDA and received FDA authorization for rolling review. ALXN1840 has Fast Track, Orphan Drug, and Rare Pediatric Disease (RPD) designations, with the RPD designation potentially entitling the company to a pediatric Priority Review Voucher (PRV) upon approval. The pivotal Phase 3 trial met its primary endpoint, demonstrating superior copper mobilization versus standard of care, with favorable safety across 266 patients.
Why this rating
NDA submission is a major clinical milestone for a small-cap biotech's lead asset. RPD designation and PRV potential add significant value through potential voucher monetization. However, approval remains uncertain and company scale ($155.5M) limits near-term revenue impact even if approved.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.